News & Press
Success Shown in Humans with Genetically Engineered Malaria Parasite Vaccine
A clinical trial with human volunteers has found that a next-generation malaria vaccine that uses genetically attenuated parasites shows a favorable safety profile, is well tolerated and stimulates an appropriate immune response, according to a study published today in Science Translational Medicine by scientists at the Center for Infectious Disease Research (CIDR) and Fred Hutchinson Cancer Research Center.
Chronic HIV-1 infection impairs superantigen-induced activation of peripheral CD4+CXCR5+PD-1+ cells, with relative preservation of recall antigen-specific responses
Journal of Acquired Immune Deficiency Syndromes
Repertoire comparison of the B-cell receptor-encoding loci in humans and rhesus macaques by next-generation sequencing
Clinical & Translational Immunology
Seattle is hub of innovation in combating infectious diseases like Ebola
The Seattle Times
Become The Cure - Brochure
No results were foundLoad more (62)
Help us save 15 million lives
A vaccine for HIV/AIDS or TB will save 15 million lives in the coming decade and we've never been closer.